Date: 2011-07-05
Type of information: R&D agreement
Compound: sclerostin antibody
Company: Amgen (USA) NASA (USA) UCB (Belgium)
Therapeutic area: Bone diseases
Type agreement: R&D
Action mechanism:
Disease: loss of bone associated with space flight
Details: Amgen and UCB are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis. The loss of bone mass during space flight remains a significant problem for human space missions, especially long-term flights. This experiment will take place aboard space shuttle Atlantis, on the final NASA shuttle mission, Space Shuttle Flight STS-135, scheduled to launch July 8, 2011. It will assess the effect of a sclerostin antibody on the loss of bone associated with space flight in mice. In this experiment of 30 space-flown mice, half of the mice are given the sclerostin antibody and the remaining mice receive a placebo. After the flight, various aspects of the structure, composition, strength, and cell and molecular nature of the bones from the flight and ground-based control mice will be analyzed.
Financial terms:
Latest news:
